Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Apr:1068:244-9.
doi: 10.1196/annals.1346.028.

Bone cell precursors and the pathophysiology of bone loss

Affiliations
Review

Bone cell precursors and the pathophysiology of bone loss

Harry C Blair et al. Ann N Y Acad Sci. 2006 Apr.

Abstract

In health, changes in bone formation and degradation rates are coupled and adequate cellular resources are available in the bone so that a change in bone formation rate occurs with an opposing change in resorption. On the other hand, the regulation of bone volume, particularly in pathological conditions, is dependent not only on the pathways that mediate terminal pathways of bone cell differentiation, but also on the availability of stem cells for allowing the differentiation to occur. Regulation of cell numbers in stem cell compartments and release of stem cells for differentiation of osteoblast or osteoclast precursors are not well understood, although it is clear that changes in stem cell numbers underlie pathological changes in bone mass. This may include effects of aging, fracture, metastatic disease, and autoimmune diseases on the precursor cell pools available for bone formation and degradation. Increases in osteoclast precursors or decreases in osteoblast precursors are common features of bone-losing states; increases in precursors may conversely occur during growth or repair processes. Rational therapy based on modifying stem cell populations may, when the processes are better understood, help prevent chronic bone-losing states and may also be of use in preventing or treating aplastic anemia and related conditions.

PubMed Disclaimer

Similar articles

Cited by

  • Impact of glucose-dependent insulinotropic peptide on age-induced bone loss.
    Ding KH, Shi XM, Zhong Q, Kang B, Xie D, Bollag WB, Bollag RJ, Hill W, Washington W, Mi QS, Insogna K, Chutkan N, Hamrick M, Isales CM. Ding KH, et al. J Bone Miner Res. 2008 Apr;23(4):536-43. doi: 10.1359/jbmr.071202. J Bone Miner Res. 2008. PMID: 18072880 Free PMC article.
  • Aging and bone.
    Boskey AL, Coleman R. Boskey AL, et al. J Dent Res. 2010 Dec;89(12):1333-48. doi: 10.1177/0022034510377791. Epub 2010 Oct 5. J Dent Res. 2010. PMID: 20924069 Free PMC article. Review.

Publication types

LinkOut - more resources